

PRESS RELEASE

03 March 2022 10:31:00 CET

Senzime wins US deal for 23 TetraGraph systems

Press release: Uppsala March 3, 2022. Senzime announces today that the company has won an order from a large American university hospital regarding 23 TetraGraph systems and with associated disposable sensors.

All operating rooms at the university hospital are equipped with TetraGraph systems. At the same time, the surgical protocol is standardized for patients who receive muscle-blocking drugs with a requirement that these will be monitored.

There are approximately 6,000 hospitals and over 50,000 operating rooms in the United States, the world's largest market for medical equipment. Senzime is selling, through a combination of its own sales force and distributors. In the United States alone, more than 20 million patients receive muscle-blocking drugs annually as part of anesthesia. These patients need to be closely monitored with the type of technology that Senzime develops and markets to ensure the correct dosage and to determine when it is safe to wake the patient after surgery.

"We have now won the procurement in another important hospital in the United States, and it is our assessment that their decision to standardize the use of objective monitoring to protect their patients from potential complications is something we will see more of.", says Pia Renaudin, CEO of Senzime

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared monitoring systems for patients undergoing anesthesia. Senzime's employees worldwide are committed to the vision of a world without anesthesia related complications. Six out of ten patients that wake up after surgery are not fully muscle recovered and therefore at risk having critical respiratory complications. The TetraGraph system helps anesthesia providers improve patient care and reduce healthcare costs by digitally and continuously measure the degree of neuromuscular blockade under and after surgery. Senzime operates in the world's leading markets targeting a market opportunity valued in excess of SEK 15 billion per year. The company's shares are listed on Nasdaq Stockholms main market (ticker SEZI). www.senzime.com

Attachments

Senzime wins US deal for 23 TetraGraph systems